Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Dissecting the molecular control of immune cell accumulation in the inflamed joint
Catriona T. Prendergast, … , James M. Brewer, Paul Garside
Catriona T. Prendergast, … , James M. Brewer, Paul Garside
Published February 22, 2022
Citation Information: JCI Insight. 2022;7(7):e151281. https://doi.org/10.1172/jci.insight.151281.
View: Text | PDF
Resource and Technical Advance Inflammation

Dissecting the molecular control of immune cell accumulation in the inflamed joint

  • Text
  • PDF
Abstract

Mechanisms governing entry and exit of immune cells into and out of inflamed joints remain poorly understood. We sought herein to identify the key molecular pathways regulating such migration. Using murine models of inflammation in conjunction with mice expressing a photoconvertible fluorescent protein, we characterized the migration of cells from joints to draining lymph nodes and performed RNA-Seq analysis on isolated cells, identifying genes associated with migration and retention. We further refined the gene list to those specific for joint inflammation. RNA-Seq data revealed pathways and genes previously highlighted as characteristic of rheumatoid arthritis in patient studies, validating the methodology. Focusing on pathways associated with cell migration, adhesion, and movement, we identified genes involved in the retention of immune cells in the inflamed joint, namely junctional adhesion molecule A (JAM-A), and identified a role for such molecules in T cell differentiation in vivo. Thus, using a combination of cell-tracking approaches and murine models of inflammatory arthritis, we identified genes, pathways, and anatomically specific tissue signatures regulating cell migration in a variety of inflamed sites. This skin- and joint-specific data set will be an invaluable resource for the identification of therapeutic targets for arthritis and other inflammatory disorders.

Authors

Catriona T. Prendergast, Robert A. Benson, Hannah E. Scales, Caio Santos Bonilha, John J. Cole, Iain McInnes, James M. Brewer, Paul Garside

×

Figure 7

JAM-A blockade in vivo attenuates CD4+ T cell proliferation and decreases T-bet and RORγt expression by recently primed T cells.

Options: View larger image (or click on image) Download as PowerPoint
JAM-A blockade in vivo attenuates CD4+ T cell proliferation and decrease...
CFSE-labeled immune cells from LNs and spleens of OT-II mice were adoptively transferred to female C57BL/6 mice that were challenged with footpad injections of LPS and 0.5 ug OVA in the presence of anti–JAM-A mAb or its IgG isotype control. Popliteal LNs were harvested 72 hours later and analyzed by flow cytometry. (A) Representative histograms of CFSE fluorescence intensity on OT-II CD4+ cells (CD4+CD45.1+) with gating on cell generations and (B) quantification of the proportion of cells in each generation. (C) Division index and (D) proliferation index of OT-II CD4+ T cells. (E) The total number of leukocytes in the draining LNs. (F) The total number of OT-II CD4+ T cells in the draining LNs. (G) Percentage T-bet+. (H) MFI of T-bet. (I) Representative histograms showing T-bet expression on OT-II CD4+ T cells. (J) Percentage RORγt+. (K) MFI of RORγt. (L) Representative histograms showing RORγt expression on OT-II CD4+ T cells. (M) Percentage FoxP3+. (N) MFI of FoxP3. (O) Representative histograms showing FoxP3 expression on OT-II CD4+ T cells. Data are from a single experiment; each symbol represents an individual animal; mean ± SD shown; n = 4. Statistical differences between the treatment groups and the OVA/LPS IgG-treated control were determined using 1-way ANOVA with Dunnett’s multiple-comparison test. *P ≤ 0.05, **P ≤ 0.01, ****P ≤ 0.0001.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts